CLINICAL_TRIALS
trial_result
· 2016-04-15
Clinical Trial Update: Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive [Phase 2]
Summary
Phase 2 safety, efficacy and dose–response study of BMS-986001 in treatment-naive HIV-1 infection has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: HIV-1 Infection | Phase 2 | Status: TERMINATED